Mesenchymal stem cell-based treatment for microvascular and secondary complications of diabetes mellitus

Frontiers in Endocrinology

Volumn 5, Issue JUN, 2014, Pages

  Davey, Grace C ^a   Patil, Swapnil B ^a   O'Loughlin, Aonghus ^b   O'Brien, Timothy ^a,b  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^b UNIVERSITY HOSPITAL GALWAY   (Ireland)

Author keywords

Diabetes; Mesenchymal stromal cell; Microvascular complication; MSC; Nephropathy; Neuropathy; Retinopathy

Indexed keywords

ANGIOGENESIS; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; FRACTURE; GLYCEMIC CONTROL; HUMAN; IMMUNOMODULATION; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW (TOPIC); TISSUE REPAIR; WOUND HEALING;

EID: 84905393423     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2014.00086     Document Type: Review

References (188)

1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care (2013) 36(Suppl 1):S67-74. doi: 10.2337/dc13-S067
2. History of diabetes mellitus. Saudi Med J (2002) 23:373-8.
3. A history of diabetes mellitus or how a disease of the kidneys evolved into a kidney disease. Adv Chronic Kidney Dis (2005) 12:223-9. doi:10.1053/j.ackd.2005.01.002
4. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract (2010) 87:4-14. doi:10.1016/j.diabres.2009.10.007
5. Definition and classification of diabetes mellitus and the criteria for diagnosis. 3rd ed. In: LeRoith D, Taylor SI, Olefsky JM editors. Diabetes Mellitus: A Fundamental and Clinical Text. Philadelphia, PA: Lippincott Williams & Wilkins (2004). p. 457-67.
6. Krolewski AS, Warram JH, Freire MB. Epidemiology of late complications of diabetes: a basis for the development and evaluation of preventive programs. 14th ed. In: Kahn CR, Weir G, King G, Jacobson A, Smith R, Moses A editors. Joslin's Diabetes Mellitus. Boston, MA: Lippincott Williams & Wilkins (2005). p. 795-808.
7. Hofmann S, Brownlee M. Biochemistry and molecular cell biology of diabetic complications: a unifying mechanism. 3rd ed. In: LeRoith D, Taylor SI, Olefsky JM editors. Diabetes Mellitus: A Fundamental and Clinical Text. Philadelphia, PA: Lippincott Williams & Wilkins (2004). p. 1441-56.
8. Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiol Rev (2013) 93:137-88. doi:10.1152/physrev.00045.2011
9. Falanga V. Wound healing and its impairment in the diabetic foot. Lancet (2005) 366:1736-43. doi:10.1016/S0140-6736(05)67700-8
10. Asghar O, Al-Sunni A, Khavandi K, Khavandi A, Withers S, Greenstein A, et al. Diabetic cardiomyopathy. Clin Sci (Lond) (2009) 116:741-60. doi:10.1042/CS20080500
11. Nouwen A, Nefs G, Caramlau I, Connock M, Winkley K, Lloyd CE, et al. European Depression in Diabetes Research Consortium. Prevalence of depression in individuals with impaired glucose metabolism or undiagnosed diabetes: a systematic review and meta-analysis of the European Depression in Diabetes (EDID) Research Consortium. Diabetes Care (2011) 34:752-62. doi:10.2337/dc10-1414
12. Thorve VS, Kshirsagar AD, Vyawahare NS, Joshi VS, Ingale KG, Mohite RJ. Diabetes-induced erectile dysfunction: epidemiology, pathophysiology and management. J Diabetes Complications (2011) 25:129-36. doi:10.1016/j.jdiacomp.2010.03.003
13. Schwartz AV, Sellmeyer DE. Diabetes, fracture, and bone fragility. Curr Osteoporos Rep (2007) 5:105-11. doi:10.1007/s11914-007-0025-x
14. Mark H, Lowitt JSD. Cutaneous manifestations of diabetes mellitus. 14th ed. In: Kahn CR, Weir G, King G, Jacobson A, Smith R, Moses A editors. Joslin's Diabetes Mellitus. Boston, MA: Lippincott Williams & Wilkins (2005). p. 1049-60.
15. Frank RN. Diabetic retinopathy. N Engl J Med (2004) 350:48-58. doi:10.1056/NEJMra021678
16. Fong DS, Aiello L, Gardner TW, King GL, Blankenship G, Cavallerano JD, et al. American diabetes association. Diabetic retinopathy. Diabetes Care (2003) 26(Suppl 1):S99-102. doi:10.2337/diacare.26.2007.S99
17. Chew EY. Pathophysiology of diabetic retinopathy. 3rd ed. In: LeRoith D, Taylor SI, Olefsky JM editors. Diabetes Mellitus: A Fundamental and Clinical Text. Philadelphia, PA: Lippincott Williams & Wilkins (2004). p. 1303-14.
18. Roy MS, Klein R, O'Colmain BJ, Klein BE, Moss SE, Kempen JH. The prevalence of diabetic retinopathy among adult type 1 diabetic persons in the United States. Arch Ophthalmol (2004) 122:546-51. doi:10.1001/archopht.122.4.546
19. Kempen JH, O'Colmain BJ, Leske MC, Haffner SM, Klein R, Moss SE, et al. Eye diseases prevalence research group the prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol (2004) 122:552-63. doi:10.1001/archopht.122.4.552
20. Klein R, Klein BE, Moss SE, Cruickshanks KJ. Relationship of hyperglycemia to the long-term incidence and progression of diabetic retinopathy. Arch Intern Med (1994) 154:2169-78. doi:10.1001/archinte.154.19.2169
21. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ (1998) 317:703-13. doi:10.1136/bmj.317.7160.703
22. Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Meta-Analysis for Eye Disease (META-EYE) Study Group. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care (2012) 35:556-64. doi:10.2337/dc11-1909
23. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The diabetes control and complications trial research group. N Engl J Med (1993) 329:977-86. doi:10.1056/NEJM199309303291401
24. Gilbertson DT, Liu J, Xue JL, Louis TA, Solid CA, Ebben JP, et al. Projecting the number of patients with end-stage renal disease in the United States to the year 2015. J Am Soc Nephrol (2005) 16:3736-41. doi:10.1681/ASN.2005010112
25. Cooper ME. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet (1998) 352:213-9. doi:10.1016/S0140-6736(98)01346-4
26. Mauer SM, Steffes MW, Ellis EN, Sutherland DE, Brown DM, Goetz FC. Structural-functional relationships in diabetic nephropathy. J Clin Invest (1984) 74:1143-55. doi:10.1172/JCI111523
27. Lehmann R, Schleicher ED. Molecular mechanism of diabetic nephropathy. Clin Chim Acta (2000) 297:135-44. doi:10.1016/S0009-8981(00)00240-0
28. Osterby R, Gall MA, Schmitz A, Nielsen FS, Nyberg G, Parving HH. Glomerular structure and function in proteinuric type 2 (non-insulin-dependent) diabetic patients. Diabetologia (1993) 36:1064-70. doi:10.1007/BF02374500
29. Pagtalunan ME, Miller PL, Jumping-Eagle S, Nelson RG, Myers BD, Rennke HG, et al. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest (1997) 99:342-8. doi:10.1172/JCI119163
30. Giunti S, Barit D, Cooper ME. Mechanisms of diabetic nephropathy: role of hypertension. Hypertension (2006) 48:519-26. doi:10.1161/01.HYP.0000240331.32352.0c
31. Mogensen CE, Keane WF, Bennett PH, Jerums G, Parving HH, Passa P, et al. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet (1995) 346:1080-4. doi:10.1016/S0140-6736(95)91747-0
32. Thomas S. Diabetic nephropathy. Medicine (2010) 38:639-43. doi:10.1016/j.mpmed.2010.09.003
33. Phillips AO. Diabetic nephropathy. Medicine (2011) 39:470-4. doi:10.1016/j.mpmed.2011.05.007
34. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med (1993) 329:1456-62. doi:10.1056/NEJM199311113292004
35. Böhlen L, de Courten M, Weidmann P. Comparative study of the effect of ACE-inhibitors and other antihypertensive agents on proteinuria in diabetic patients. Am J Hypertens (1994) 7:84S-92S.
36. Dyck PJ, Kratz KM, Karnes JL, Litchy WJ, Klein R, Pach JM, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology (1993) 43:817-24. doi:10.1212/WNL.43.4.817
37. Farmer KL, Li C, Dobrowsky RT. Diabetic peripheral neuropathy: should chaperone accompany our therapeutic approach? Pharmacol Rev (2012) 64:880-900. doi:10.1124/pr.111.005314
38. Waterman RS, Morgenweck J, Nossaman BD, Scandurro AE, Scandurro SA, Betancourt AM. Anti-inflammatory mesenchymal stem cells (MSC2) attenuate symptoms of painful diabetic peripheral Neuropathy. Stem Cells Trans Med (2012) 1:557-65. doi:10.5966/sctm.2012-0025
39. Han JW, Sin MY, Yoon YS. Cell therapy for diabetic neuropathy using adult stem or progenitor cells. Diabetes Metab J (2013) 37:91-105. doi:10.4093/dmj.2013.37.2.91
40. O'Loughlin A, McIntosh C, Dinneen SF, O'Brien T. Review paper: basic concepts to novel therapies: a review of the diabetic foot. Int J Low Extrem Wounds (2010) 9:90-102. doi:10.1177/1534734610371600
41. Vinik AI, Casellini CM. Guidelines in the management of diabetic nerve pain: clinical utility of pregabalin. Diabetes Metab Syndr Obes (2013) 6:57-78. doi:10.2147/DMSO.S24825
42. Busik JV, Tikhonenko M, Bhatwadekar A, Opreanu M, Yakubova N, Caballero S, et al. Diabetic retinopathy is associated with bone marrow neuropathy and a depressed peripheral clock. J Exp Med (2009) 206:2897-906. doi:10.1084/jem.20090889
43. Tesfaye S, Boulton AJ, Dickenson AH. Mechanisms and management of diabetic painful distal symmetrical polyneuropathy. Diabetes Care (2013) 36:2456-65. doi:10.2337/dc12-1964
44. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy (2006) 8:315-7. doi:10.1080/14653240600855905
45. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. Science (1999) 284:143-7. doi:10.1126/science.284.5411.143
46. De Ugarte DA, Morizono K, Elbarbary A, Alfonso Z, Zuk PA, Zhu M, et al. Comparison of multi-lineage cells from human adipose tissue and bone marrow. Cells Tissues Organs (2003) 174:101-9. doi:10.1159/000071150
47. Mackay AM, Beck SC, Murphy JM, Barry FP, Chichester CO, Pittenger MF. Chondrogenic differentiation of cultured human mesenchymal stem cells from marrow. Tissue Eng (1998) 4:415-28. doi:10.1089/ten.1998.4.415
48. Tropel P, Platet N, Platel JC, Noël D, Albrieux M, Benabid AL, et al. Functional neuronal differentiation of bone marrow-derived mesenchymal stem cells. Stem Cells (2006) 24:2868-76. doi:10.1634/stemcells.2005-0636
49. Ferrari G, Cusella-De Angelis G, Coletta M, Paolucci E, Stornaiuolo A, Cossu G, et al. Muscle regeneration by bone marrow-derived myogenic progenitors. Science (1998) 279:1528-30. doi:10.1126/science.279.5356.1528
50. Portmann-Lanz CB, Schoeberlein A, Huber A, Sager R, Malek A, Holzgreve W, et al. Placental mesenchymal stem cells as potential autologous graft for pre- and perinatal neuroregeneration. Am J Obstet Gynecol (2006) 194:664-73. doi:10.1016/j.ajog.2006.01.101
51. Musina RA, Belyavski AV, Tarusova OV, Solovyova EV, Sukhikh GT. Endometrial mesenchymal stem cells isolated from the menstrual blood. Bull Exp Biol Med (2008) 145:539-43. doi:10.1007/s10517-008-0136-0
52. Steigman SA, Fauza DO. Isolation of mesenchymal stem cells from amniotic fluid and placenta. Curr Protoc Stem Cell Biol (2007) 1:.1-1. doi:10.1002/9780470151808.sc01e02s1
53. Tirino V, Paino F, d'Aquino R, Desiderio V, De Rosa A, Papaccio G. Methods for the identification, characterization and banking of human DPSCs: current strategies and perspectives. Stem Cell Rev (2011) 7:608-15. doi:10.1007/s12015-011-9235-9
54. Volarevic V, Arsenijevic N, Lukic ML, Stojkovic M. Concise review: mesenchymal stem cell treatment of the complications of diabetes mellitus. Stem Cells (2011) 29:5-10. doi:10.1002/stem.556
55. Uccelli A, Pistoia V, Moretta L. Mesenchymal stem cells: a new strategy for immunosuppression? Trends Immunol (2007) 28:219-26. doi:10.1016/j.it.2007.03.001
56. Shi Y, Hu G, Su J, Li W, Chen Q, Shou P, et al. Mesenchymal stem cells: a new strategy for immunosuppression and tissue repair. Cell Res (2010) 20:510-8. doi:10.1038/cr.2010.44
57. Duffy MM, Ritter T, Ceredig R, Griffin MD. Mesenchymal stem cell effects on T-cell effector pathways. Stem Cell Res Ther (2011) 2:34. doi:10.1186/scrt75
58. Duffy MM, Pindjakova J, Hanley SA, McCarthy C, Weidhofer GA, Sweeney EM, et al. Mesenchymal stem cell inhibition of T-helper 17 cell-differentiation is triggered by cell-cell contact and mediated by prostaglandin E2 via the EP4 receptor. Eur J Immunol (2011) 41:2840-51. doi:10.1002/eji.201141499
59. Sullivan C, Murphy JM, Griffin MD, Porter RM, Evans CH, O'Flatharta C, et al. Genetic mismatch affects the immunosuppressive properties of mesenchymal stem cells in vitro and their ability to influence the course of collagen-induced arthritis. Arthritis Res Ther (2012) 14:R167. doi:10.1186/ar3916
60. Sullivan C, Barry F, Ritter T, O'Flatharta C, Howard L, Shaw G, et al. Allogeneic murine mesenchymal stem cells: migration to inflamed joints in vivo and amelioration of collagen induced arthritis when transduced to express CTLA4Ig. Stem Cells Dev (2013) 22:3203-13. doi:10.1089/scd.2013.0248
61. Eming SA, Krieg T, Davidson JM. Inflammation in wound repair: molecular and cellular mechanisms. J Invest Dermatol (2007) 127:514-25. doi:10.1038/sj.jid.5700701
62. Luster AD, Alon R, von Andrian UH. Immune cell migration in inflammation: present and future therapeutic targets. Nat Immunol (2005) 6:1182-90. doi:10.1038/ni1275
63. Krysko Krysko DV, Denecker G, Festjens N, Gabriels S, Parthoens E, D'Herde K, et al. Macrophages use different internalization mechanisms to clear apoptotic and necrotic cells. Cell Death Differ (2006) 13:2011-22. doi:10.1038/sj.cdd.4401900
64. Shi Y, Su J, Roberts AI, Shou P, Rabson AB, Ren G. How mesenchymal stem cells interact with tissue immune responses. Trends Immunol (2012) 33:136-43. doi:10.1016/j.it.2011.11.004
65. Ma XL, Liu KD, Li FC, Jiang XM, Jiang L, Li HL. Human mesenchymal stem cells increases expression of a-tubulin and angiopoietin 1 and 2 in focal cerebral ischemia and reperfusion. Curr Neurovasc Res (2013) 10:103-11. doi:10.2174/1567202611310020003
66. Aguilar S, Scotton CJ, McNulty K, Nye E, Stamp G, Laurent G, et al. Bone marrow stem cells expressing keratinocyte growth factor via an inducible lentivirus protects against bleomycin-induced pulmonary fibrosis. PLoS One (2009) 4:e8013. doi:10.1371/journal.pone.0008013
67. Hung SP, Yang MH, Tseng KF, Lee OK. Hypoxia-induced secretion of TGF-beta 1 in mesenchymal stem cell promotes breast cancer cell progression. Cell Transplant (2012) 22:1869-82. doi:10.3727/096368912X657954
68. Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells. Blood (2007) 110:3499-506. doi:10.1182/blood-2007-02-069716
69. Abdi R, Fiorina P, Adra CN, Atkinson M, Sayegh MH. Immunomodulation by mesenchymal stem cells: a potential therapeutic strategy for type 1 diabetes. Diabetes (2008) 57:1759-67. doi:10.2337/db08-0180
70. Volarevic V, Al-Qahtani A, Arsenijevic N, Pajovic S, Lukic ML. Interleukin-1 receptor antagonist (IL-1Ra) and IL-1Ra producing mesenchymal stem cells as modulators of diabetogenesis. Autoimmunity (2010) 43:255-63. doi:10.3109/08916930903305641
71. Nauta AJ, Westerhuis G, Kruisselbrink AB, Lurvink EG, Willemze R, Fibbe WE. Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood (2006) 108:2114-20. doi:10.1182/blood-2005-11-011650
72. Eliopoulos N, Stagg J, Lejeune L, Pommey S, Galipeau J. Allogeneic marrow stromal cells are immune rejected by MHC class I- and class II-mismatched recipient mice. Blood (2005) 106:4057-65. doi:10.1182/blood-2005-03-1004
73. Van Laar JM, Tyndall A. Adult stem cells in the treatment of autoimmune diseases. Rheumatology (Oxford) (2006) 45:1187-93. doi:10.1093/rheumatology/kel158
74. Augello A, Tasso R, Negrini SM, Cancedda R, Pennesi G. Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritis. Arthritis Rheum (2007) 56:1175-86. doi:10.1002/art.22511
75. Deng W, Han Q, Liao L, You S, Deng H, Zhao RC. Effects of allogeneic bone marrow-derived mesenchymal stem cells on T and B lymphocytes from BXSB mice. DNA Cell Biol (2005) 24:458-63. doi:10.1089/dna.2005.24.458
76. Gerdoni E, Gallo B, Casazza S, Musio S, Bonanni I, Pedemonte E, et al. Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis. Ann Neurol (2007) 61:219-27. doi:10.1002/ana.21076
77. Bai L, Lennon DP, Eaton V, Maier K, Caplan AI, Miller SD, et al. Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis. Glia (2009) 57:1192-203. doi:10.1002/glia.20841
78. Lee RH, Seo MJ, Reger RL, Spees JL, Pulin AA, Olson SD, et al. Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice. Proc Natl Acad Sci USA (2006) 103:17438-43. doi:10.1073/pnas.0608249103
79. Poncelet AJ, Vercruysse J, Saliez A, Gianello P. Although pig allogeneic mesenchymal stem cells are not immunogenic in vitro, intracardiac injection elicits an immune response in vivo. Transplantation (2007) 83:783-90. doi:10.1097/01.tp.0000258649.23081.a3
80. Schu S, Nosov M, O'Flynn L, Shaw G, Treacy O, Barry F, et al. Immunogenicity of allogeneic mesenchymal stem cells. J Cell Mol Med (2012) 16:2094-103. doi:10.1111/j.1582-4934.2011.01509.x
81. Griffin MD, Ryan AE, Alagesan S, Lohan P, Treacy O, Ritter T. Anti-donor immune responses elicited by allogeneic mesenchymal stem cells: what have we learned so far? Immunol Cell Biol (2013) 91:40-51. doi:10.1038/icb.2012.67
82. Oh SH, Muzzonigro TM, Bae SH, LaPlante JM, Hatch HM, Petersen BE. Adult bone marrow-derived cells trans-differentiating into insulin-producing cells for the treatment of type I diabetes. Lab Invest (2004) 84:607-17. doi:10.1038/labinvest.3700074
83. Dong QY, Chen L, Gao GQ, Wang L, Song J, Chen B, et al. Allogeneic diabetic mesenchymal stem cells transplantation in streptozotocin induced diabetic rat. Clin Invest Med (2008) 31:E328-37.
84. Xie QP, Huang H, Xu B, Dong X, Gao SL, Zhang B, et al. Human bone marrow mesenchymal stem cells differentiate into insulin-producing cells upon microenvironmental manipulation in vitro. Differentiation (2009) 77:483-91. doi:10.1016/j.diff.2009.01.001
85. Sun Y, Chen L, Hou XG, Hou WK, Dong JJ, Sun L, et al. Differentiation of bone marrow-derived mesenchymal stem cells from diabetic patients into insulin-producing cells in vitro. Chin Med J (2007) 120:771-776.
86. Ezquer FE, Ezquer ME, Parrau DB, Carpio D, Yanez AJ, Conget PA. Systemic administration of multipotent mesenchymal stromal cells reverts hyperglycemia and prevents nephropathy in type 1 diabetic mice. Biol Blood Marrow Transplant (2008) 14:631-40. doi:10.1016/j.bbmt.2008.01.006
87. Madec AM, Mallone R, Afonso G, Abou Mrad E, Mesnier A, Eljaafari A, et al. Mesenchymal stem cells protect NOD mice from diabetes by inducing regulatory T cells. Diabetologia (2009) 52:1391-9. doi:10.1007/s00125-009-1374-z
88. Ito T, Itakura S, Todorov I, Rawson J, Asari S, Shintaku J, et al. Mesenchymal stem cell and islet co-transplantation promotes graft revascularization and function. Transplantation (2010) 89:1438-45. doi:10.1097/TP.0b013e3181db09c4
89. Hao H, Liu J, Shen J, Zhao Y, Liu H, Hou Q, et al. Multiple intravenous infusions of bone marrow mesenchymal stem cells reverse hyperglycemia in experimental type 2 diabetes rats. Biochem Biophys Res Commun (2013) 436:418-23. doi:10.1016/j.bbrc.2013.05.117
90. Botero D, Wolfsdorf JI. Diabetes mellitus in children and adolescents. Arch Med Res (2005) 36:281-90. doi:10.1016/j.arcmed.2004.12.002
91. Turner RC, Holman RR. Lessons from UK prospective diabetes study. Diabetes Res Clin Pract (1995) 28:S151-7. doi:10.1016/0168-8227(95)01105-M
92. Engerman RL, Kern TS. Retinopathy in animal models of diabetes. Diabetes Metab Rev (1995) 11:109-20. doi:10.1002/dmr.5610110203
93. Calcutt NA, Cooper ME, Kern TS, Schmidt AM. Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials. Nat Rev Drug Discov (2009) 8:417-29. doi:10.1038/nrd2476
94. Madan A, Penn JS. Animal models of oxygen induced retinopathy. Front Biosci (2003) 8:d1030-43. doi:10.2741/1056
95. Ohno-Matsui K, Hirose A, Yamamoto S, Saikia J, Okamoto N, Gehlbach P, et al. Inducible expression of vascular endothelial growth factor in adult mice causes severe proliferative retinopathy and retinal detachment. Am J Pathol (2002) 160:711-9. doi:10.1016/S0002-9440(10)64891-2
96. Ruberte J, Ayuso E, Navarro M, Carretero A, Nacher V, Haurigot V, et al. Increased ocular levels of IGF-1 in transgenic mice lead to diabetes-like eye disease. J Clin Invest (2004) 113:1149-57. doi:10.1172/JCI19478
97. Brunner S, Schernthaner GH, Satler M, Elhenicky M, Hoellerl F, Schmid-Kubista KE, et al. Correlation of different circulating endothelial progenitor cells to stages of diabetic retinopathy: first in vivo data. Invest Ophthalmol Vis Sci (2009) 50:392-8. doi:10.1167/iovs.08-1748
98. Lee IG, Chae SL, Kim JC. Involvement of circulating endothelial progenitor cells and vasculogenic factors in the pathogenesis of diabetic retinopathy. Eye (Lond) (2006) 20:546-52. doi:10.1038/sj.eye.6701920
99. Grant MB, May WS, Caballero S, Brown GA, Guthrie SM, Mames RN, et al. Adult hematopoietic stem cells provide functional hemangioblast activity during retinal neovascularisation. Nat Med (2002) 8:607-12. doi:10.1038/nm0602-607
100. Ritter MR, Banin E, Moreno SK, Aguilar E, Dorrell MI, Friedlander M. Myeloid progenitors differentiate into microglia and promote vascular repair in a model of ischemic retinopathy. J Clin Invest (2006) 116:3266-76. doi:10.1172/JCI29683
101. Yang Z, Li K, Yan X, Dong F, Zhao C. Amelioration of diabetic retinopathy by engrafted human adipose-derived mesenchymal stem cells in streptozotocin diabetic rats. Graefes Arch Clin Exp Ophthalmol (2010) 248:1415-22. doi:10.1007/s00417-010-1384-z
102. Otani A, Dorrell MI, Kinder K, Moreno SK, Nusinowitz S, Banin E, et al. Rescue of retinal degeneration by intravitreally injected adult bone marrow-derived lineage-negative hematopoietic stem cells. J Clin Invest (2004) 114:765-74. doi:10.1172/JCI200421686
103. Tomita M, Adachi Y, Yamada H, Takahashi K, Kiuchi K, Oyaizu H, et al. Bone marrow-derived stem cells can differentiate into retinal cells in injured rat retina. Stem Cells (2002) 20:279-83. doi:10.1634/stemcells.20-4-279
104. Otani A, Kinder K, Ewalt K, Otero FJ, Schimmel P, Friedlander M. Bone marrow-derived stem cells target retinal astrocytes and can promote or inhibit retinal angiogenesis. Nat Med (2002) 8:1004-10. doi:10.1038/nm744
105. Inoue Y, Iriyama A, Ueno S, Takahashi H, Kondo M, Tamaki Y, et al. Subretinal transplantation of bone marrow mesenchymal stem cells delays retinal degeneration in the RCS rat model of retinal degeneration. Exp Eye Res (2007) 85:234-41. doi:10.1016/j.exer.2007.04.007
106. Wang S, Lu B, Girman S, Duan J, McFarland T, Zhang QS, et al. Non-invasive stem cell therapy in a rat model for retinal degeneration and vascular pathology. PLoS One (2010) 5:e9200. doi:10.1371/journal.pone.0009200
107. Scalinci SZ, Scorolli L, Corradetti G, Domanico D, Vingolo EM, Meduri A, et al. Potential role of intravitreal human placental stem cell implants in inhibiting progression of diabetic retinopathy in type 2 diabetes: neuroprotective growth factors in the vitreous. Clin Ophthalmol (2011) 5:691-6. doi:10.2147/OPTH.S21161
108. Mottaghi S, Larijani B, Sharifi AM. Atorvastatin: an efficient step forward in mesenchymal stem cell therapy of diabetic retinopathy. Cytotherapy (2013) 15:263-6. doi:10.1016/j.jcyt.2012.11.002
109. Ezquer F, Ezquer M, Simon V, Pardo F, Yañez A, Carpio D, et al. Endovenous administration of bone marrow-derived multipotent mesenchymal stromal cells prevents renal failure in diabetic mice. Biol Blood Marrow Transplant (2009) 15:1354-65. doi:10.1016/j.bbmt.2009.07.022
110. Zhou H, Tian HM, Long Y, Zhang XX, Zhong L, Deng L, et al. Mesenchymal stem cells transplantation mildly ameliorates experimental diabetic nephropathy in rats. Chin Med J (Engl) (2009) 122:2573-9.
111. Park JH, Park J, Hwang SH, Han H, Ha H. Delayed treatment with human umbilical cord blood-derived stem cells attenuates diabetic renal injury. Transplant Proc (2012) 44:1123-6. doi:10.1016/j.transproceed.2012.03.044
112. Park JH, Hwang I, Hwang SH, Han H, Ha H. Human umbilical cord blood-derived mesenchymal stem cells prevent diabetic renal injury through paracrine action. Diabetes Res Clin Pract (2012) 98:465-73. doi:10.1016/j.diabres.2012.09.034
113. Fang Y, Tian X, Bai S, Fan J, Hou W, Tong H, et al. Autologous transplantation of adipose-derived mesenchymal stem cells ameliorates streptozotocin-induced diabetic nephropathy in rats by inhibiting oxidative stress, pro-inflammatory cytokines and the p38 MAPK signaling pathway. Int J Mol Med (2012) 30:85-92. doi:10.3892/ijmm.2012.977
114. Li D, Wang N, Zhang L, Hanyu Z, Xueyuan B, Fu B, et al. Mesenchymal stem cells protect podocytes from apoptosis induced by high glucose via secretion of epithelial growth factor. Stem Cell Res Ther (2013) 4:103. doi:10.1186/scrt314
115. Wang S, Li Y, Zhao J, Zhang J, Huang Y. Mesenchymal stem cells ameliorate podocyte injury and proteinuria in a type 1 diabetic nephropathy rat model. Biol Blood Marrow Transplant (2013) 19:538-46. doi:10.1016/j.bbmt.2013.01.001
116. Lv SS, Liu G, Wang JP, Wang WW, Cheng J, Sun AL, et al. Mesenchymal stem cells transplantation ameliorates glomerular injury in streptozotocin-induced diabetic nephropathy in rats via inhibiting macrophage infiltration. Int Immunopharmacol (2013) 17:275-82. doi:10.1016/j.intimp.2013.05.031
117. Zhang Y, Ye C, Wang G, Gao Y, Tan K, Zhuo Z, et al. Kidney-targeted transplantation of mesenchymal stem cells by ultrasound-targeted microbubble destruction promotes kidney repair in diabetic nephropathy rats. Biomed Res Int (2013) 2013:526367. doi:10.1155/2013/526367
118. Shibata T, Naruse K, Kamiya H, Kozakae M, Kondo M, Yasuda Y, et al. Transplantation of bone marrow-derived mesenchymal stem cells improves diabetic polyneuropathy in rats. Diabetes (2008) 57:3099-107. doi:10.2337/db08-0031
119. Quertainmont R, Cantinieaux D, Botman O, Sid S, Schoenen J, Franzen R. Mesenchymal stem cell graft improves recovery after spinal cord injury in adult rats through neurotrophic and pro-angiogenic actions. PLoS One (2012) 7:e39500. doi:10.1371/journal.pone.0039500
120. Hsieh JY, Wang HW, Chang SJ, Liao KH, Lee IH, Lin WS, et al. Mesenchymal stem cells from human umbilical cord express preferentially secreted factors related to neuroprotection, neurogenesis, and angiogenesis. PLoS One (2013) 8:e72604. doi:10.1371/journal.pone.0072604
121. Kim BJ, Jin HK, Bae JS. Bone marrow-derived mesenchymal stem cells improve the functioning of neurotrophic factors in a mouse model of diabetic neuropathy. Lab Anim Res (2011) 27:171-6. doi:10.5625/lar.2011.27.2.171
122. Wang Y, Xue M, Xuan YL, Hu HS, Cheng WJ, Suo F, et al. Mesenchymal stem cell therapy improves diabetic cardiac autonomic neuropathy and decreases the inducibility of ventricular arrhythmias. Heart Lung Circ (2013) 22:1018-25. doi:10.1016/j.hlc.2013.06.007
123. Waterman RS, Betancourt AM. Treating chronic pain with mesenchymal stem cells: a therapeutic approach worthy of continued investigation. J Stem Cell Res Ther (2011) S2:001. doi:10.4172/2157-7633.S2-001
124. Jarajapu YP, Grant MB. The promise of cell-based therapies for diabetic complications: challenges and solutions. Circ Res (2010) 106:854-69. doi:10.1161/CIRCRESAHA.109.213140
125. Bernardi S, Severini GM, Zauli G, Secchiero P. Cell-based therapies for diabetic complications. Exp Diabetes Res (2012) 2012:872504. doi:10.1155/2012/872504
126. Stepanovic V, Awad O, Jiao C, Dunnwald M, Schatteman GC. Leprdb diabetic mouse bone marrow cells inhibit skin wound vascularisation but promote wound healing. Circ Res (2003) 92:1247-53. doi:10.1161/01.RES.0000074906.98021.55
127. Wu Y, Chen L, Scott PG, Tredget EE. Mesenchymal stem cells enhance wound healing through differentiation and angiogenesis. Stem Cells (2007) 25:2648-59. doi:10.1634/stemcells.2007-0226
128. Javazon EH, Keswani SG, Badillo AT, Crombleholme TM, Zoltick PW, Radu AP, et al. Enhanced epithelial gap closure and increased angiogenesis in wounds of diabetic mice treated with adult murine bone marrow stromal progenitor cells. Wound Repair Regen (2007) 15:350-359. doi:10.1111/j.1524-475X.2007.00237.x
129. Kwon DS, Gao X, Liu YB, Dulchavsky DS, Danyluk AL, Bansal M, et al. Treatment with bone marrow-derived stromal cells accelerates wound healing in diabetic rats. Int Wound J (2008) 5:453-463. doi:10.1111/j.1742-481X.2007.00408.x
130. Falanga V, Iwamoto S, Chartier M, Yufit T, Butmarc J, Kouttab N, et al. Autologous bone marrow-derived cultured mesenchymal stem cells delivered in a fibrin spray accelerate healing in murine and human cutaneous wounds. Tissue Eng (2007) 13:1299-312. doi:10.1089/ten.2006.0278
131. McFarlin K, Gao X, Liu YB, Dulchavsky DS, Kwon D, Arbab AS, et al. Bone marrow-derived mesenchymal stromal cells accelerate wound healing in the rat. Wound Repair Regen (2006) 14:471-8. doi:10.1111/j.1743-6109.2006.00153.x
132. Amin AH, Abd Elmageed ZY, Nair D, Partyka MI, Kadowitz PJ, Belmadani S, et al. Modified multipotent stromal cells with epidermal growth factor restore vasculogenesis and blood flow in ischemic hind-limb of type II diabetic mice. Lab Invest (2010) 90:985-96. doi:10.1038/labinvest.2010.86
133. Maharlooei MK, Bagheri M, Solhjou Z, Jahromi BM, Akrami M, Rohani L, et al. Adipose tissue derived mesenchymal stem cell (AD-MSC) promotes skin wound healing in diabetic rats. Diabetes Res Clin Pract (2011) 93:228-34. doi:10.1016/j.diabres.2011.04.018
134. O'Loughlin A, Kulkarni M, Creane M, Vaughan EE, Mooney E, Shaw G, et al. Topical administration of allogeneic mesenchymal stromal cells seeded in a collagen scaffold augments wound healing and increases angiogenesis in the diabetic rabbit ulcer. Diabetes (2013) 62:2588-94. doi:10.2337/db12-1822
135. Humpert PM, Bärtsch U, Konrade I, Hammes HP, Morcos M, Kasper M, et al. Locally applied mononuclear bone marrow cells restore angiogenesis and promote wound healing in a type 2 diabetic patient. Exp Clin Endocrinol Diabetes (2005) 113:538-40. doi:10.1055/s-2005-872886
136. Vojtassák J, Danisovic L, Kubes M, Bakos D, Jarábek L, Ulicná M, et al. Autologous biograft and mesenchymal stem cells in treatment of the diabetic foot. Neuro Endocrinol Lett (2006) 27(Suppl 2):134-7.
137. Kirana S, Stratmann B, Lammers D, Negrean M, Stirban A, Minartz P, et al. Wound therapy with autologous bone marrow stem cells in diabetic patients with ischaemia-induced tissue ulcers affecting the lower limbs. Int J Clin Pract (2007) 61:690-2. doi:10.1111/j.1742-1241.2007.01303.x
138. Yoshikawa T, Mitsuno H, Nonaka I, Sen Y, Kawanishi K, Inada Y, et al. Wound therapy by marrow mesenchymal cell transplantation. Plast Reconstr Surg (2008) 121:860-77. doi:10.1097/01.prs.0000299922.96006.24
139. Dash NR, Dash SN, Routray P, Mohapatra S, Mohapatra PC. Targeting nonhealing ulcers of lower extremity in human through autologous bone marrow-derived mesenchymal stem cells. Rejuvenation Res (2009) 12:359-66. doi:10.1089/rej.2009.0872
140. Kirana S, Stratmann B, Prante C, Prohaska W, Koerperich H, Lammers D, et al. Autologous stem cell therapy in the treatment of limb ischaemia induced chronic tissue ulcers of diabetic foot patients. Int J Clin Pract (2012) 66:384-93. doi:10.1111/j.1742-1241.2011.02886.x
141. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis epidemiology, pathophysiology, and management. JAMA (2002) 287:2570-81. doi:10.1001/jama.287.19.2570
142. Secchiero P, Candido R, Corallini F, Zacchigna S, Toffoli B, Rimondi E, et al. Systemic tumor necrosis factor-related apoptosis-inducing ligand delivery shows antiatherosclerotic activity in apolipoprotein E-null diabetic mice. Circulation (2006) 114:1522-30. doi:10.1161/CIRCULATIONAHA.106.643841
143. Poornima IG, Parikh P, Shannon RP. Diabetic cardiomyopathy: the search for a unifying hypothesis. Circ Res (2006) 98:596-605. doi:10.1161/01.RES.0000207406.94146.c2
144. Camp TM, Tyagi SC, Senior RM, Hayden MR, Tyagi SC. Gelatinase B (MMP-9) an apoptotic factor in diabetic transgenic mice. Diabetologia (2003) 46:1438-45. doi:10.1007/s00125-003-1200-y
145. Yoon YS, Uchida S, Masuo O, Cejna M, Park JS, Gwon HC, et al. Progressive attenuation of myocardial vascular endothelial growth factor expression is a seminal event in diabetic cardiomyopathy: restoration of microvascular homeostasis and recovery of cardiac function in diabetic cardiomyopathy after replenishment of local vascular endothelial growth factor. Circulation (2005) 111:2073-85.
146. Zhang N, Li J, Luo R, Jiang J, Wang JA. Bone marrow mesenchymal stem cells induce angiogenesis and attenuate the remodeling of diabetic cardiomyopathy. Exp Clin Endocrinol Diabetes (2008) 116:104-11. doi:10.1055/s-2007-985154
147. Li JH, Zhang N, Wang JA. Improved anti-apoptotic and anti-remodeling potency of bone marrow mesenchymal stem cells by anoxic pre-conditioning in diabetic cardiomyopathy. J Endocrinol Invest (2008) 31:103-10. doi:10.1007/BF03345575
148. Khan M, Ali F, Mohsin S, Akhtar S, Mehmood A, Choudhery MS, et al. Preconditioning diabetic mesenchymal stem cells with myogenic medium increases their ability to repair diabetic heart. Stem Cell Res Ther (2013) 4:58. doi:10.1186/scrt207
149. Calligaris SD, Conget P. Intravenous administration of bone marrow-derived multipotent mesenchymal stromal cells has a neutral effect on obesity-induced diabetic cardiomyopathy. Biol Res (2013) 46:251-5. doi:10.4067/S0716-97602013000300005
150. Nagaya N, Kangawa K, Itoh T, Iwase T, Murakami S, Miyahara Y, et al. Transplantation of mesenchymal stem cells improves cardiac function in a rat model of dilated cardiomyopathy. Circulation (2005) 112:1128-35. doi:10.1161/CIRCULATIONAHA.104.500447
151. Wang X, Zhao T, Huang W, Wang T, Qian J, Xu M, et al. Hsp20-engineered mesenchymal stem cells are resistant to oxidative stress via enhanced activation of Akt and increased secretion of growth factors. Stem Cells (2009) 27:3021-31. doi:10.1002/stem.230
152. Shabbir A, Zisa D, Suzuki G, Lee T. Heart failure therapy mediated by the trophic activities of bone marrow mesenchymal stem cells: a noninvasive therapeutic regimen. Am J Physiol Heart Circ Physiol (2009) 296:H1888-97. doi:10.1152/ajpheart.00186.2009
153. Chen SL, Fang WW, Ye F, Liu YH, Qian J, Shan SJ, et al. Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. Am J Cardiol (2004) 94:92-5. doi:10.1016/j.amjcard.2004.03.034
154. Hare JM, Traverse JH, Henry TD, Dib N, Strumpf RK, Schulman SP, et al. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol (2009) 54:2277-86. doi:10.1016/j.jacc.2009.06.055
155. Williams AR, Trachtenberg B, Velazquez DL, McNiece I, Altman P, Rouy D, et al. Intramyocardial stem cell injection in patients with ischemic cardiomyopathy: functional recovery and reverse remodeling. Circ Res (2011) 108:792-6. doi:10.1161/CIRCRESAHA.111.242610
156. Williams AR, Hare JM. Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circ Res (2011) 109:923-40. doi:10.1161/CIRCRESAHA.111.243147
157. Cashman TJ, Gouon-Evans V, Costa KD. Mesenchymal stem cells for cardiac therapy: practical challenges and potential mechanisms. Stem Cell Rev (2013) 9:254-65. doi:10.1007/s12015-012-9375-6
158. Adami S. Bone health in diabetes: considerations for clinical management. Curr Med Res Opin (2009) 25:1057-72. doi:10.1185/03007990902801147
159. Janghorbani M, Hu FB, Willett WC, Li TY, Manson JE, Logroscino G, et al. Prospective study of type 1 and 2 diabetes and risk of stroke subtypes: the Nurse's Health Study. Diabetes Care (2007) 30:1730-5. doi:10.2337/dc07-1493
160. Ahmed LA, Joakimsen RM, Berntsen GK, Fønnebø V, Schirmer H. Diabetes mellitus and the risk of non-vertebral fractures: the Tromso study. Osteoporos Int (2006) 17:495-500. doi:10.1007/s00198-005-0003-z
161. Lipscombe LL, Jamal SA, Booth GL, Hawker GA. The risk of hip fractures in older individuals with diabetes: a population-based study. Diabetes Care (2007) 30:835-41. doi:10.2337/dc06-1851
162. Janghorbani M, Van Dam RM, Willett WC, Hu FB. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol (2007) 166:495-505. doi:10.1093/aje/kwm106
163. Einhorn TA, Boskey AL, Gundberg CM, Vigorita VJ, Devlin VJ, Beyer MM. The mineral and mechanical properties of bone in chronic experimental diabetes. J Orthop Res (1988) 6:317-23. doi:10.1002/jor.1100060303
164. Reddy GK, Stehno-Bittel L, Hamade S, Enwemeka CS. The biomechanical integrity of bone in experimental diabetes. Diabetes Res Clin Pract (2001) 54:1-8. doi:10.1016/S0168-8227(01)00273-X
165. Fleischli JG, Laughlin TJ, Athanasiou K, Lanctot DR, Lavery L, Wang X, et al. Effect of diabetes mellitus on the material properties of the distal tibia. J Am Podiatr Med Assoc (2006) 96:91-5. doi:10.7547/0960091
166. Paul RG, Bailey AJ. Glycation of collagen: the basis of its central role in the late complications of ageing and diabetes. Int J Biochem Cell Biol (1996) 28:1297-310. doi:10.1016/S1357-2725(96)00079-9
167. Moseley KF. Type 2 diabetes and bone fractures. Curr Opin Endocrinol Diabetes Obes (2012) 19:128-35. doi:10.1097/MED.0b013e328350a6e1
168. Kanczler JM, Oreffo RO. Osteogenesis and angiogenesis: the potential for engineering bone. Eur Cell Mater (2008) 15:100-14.
169. Wang CY, Yang HB, Hsu HS, Chen LL, Tsai CC, Tsai KS, et al. Mesenchymal stem cell-conditioned medium facilitates angiogenesis and fracture healing in diabetic rats. J Tissue Eng Regen Med (2012) 6:559-69. doi:10.1002/term.461
170. Jaiswal N, Haynesworth SE, Caplan AI, Bruder SP. Osteogenic differentiation of purified, culture expanded human mesenchymal stem cells in vitro. J Cell Biochem (1997) 64:295-312. doi:10.1002/(SICI)1097-4644(199702)64:2<295::AID-JCB12>3.3.CO;2-6
171. Bruder SP, Fink DJ, Caplan AI. Mesenchymal stem cells in bone development, bone repair, and skeletal regeneration therapy. J Cell Biochem (1994) 56:283-94. doi:10.1002/jcb.240560303
172. Huang YC, Kaigler D, Rice KG, Krebsbach PH, Mooney DJ. Combined angiogenic and osteogenic factor delivery enhances bone marrow stromal cell-driven bone regeneration. J Bone Miner Res (2005) 20:848-57. doi:10.1359/JBMR.041226
173. Yu M, Zhou W, Song Y, Yu F, Li D, Na S, et al. Development of mesenchymal stem cell-implant complexes by cultured cells sheet enhances osseointegration in type 2 diabetic rat model. Bone (2011) 49:387-94. doi:10.1016/j.bone.2011.05.025
174. Tsuchida H, Hashimoto J, Crawford E, Manske P, Lou J. Engineered allogeneic mesenchymal stem cells repair femoral segmental defect in rats. J Orthop Res (2003) 21:44-53. doi:10.1016/S0736-0266(02)00108-0
175. Arinzeh TL, Peter SJ, Archambault MP, van denBos C, Gordon S, Kraus K, et al. Allogeneic mesenchymal stem cells regenerate bone in a critical-sized canine segmental defect. J Bone Joint Surg Am (2003) 85:1927-35.
176. Horwitz EM, Gordon PL, Koo WK, Marx JC, Neel MD, McNall RY, et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone. Proc Natl Acad Sci U S A (2002) 99:8932-7. doi:10.1073/pnas.132252399
177. Cahill RA, Wenkert D, Perlman SA, Steele A, Coburn SP, McAlister WH, et al. Infantile hypophosphatasia: transplantation therapy trial using bone fragments and cultured osteoblasts. J Clin Endocrinol Metab (2007) 92:2923-30. doi:10.1210/jc.2006-2131
178. Whyte MP, Kurtzberg J, McAlister WH, Mumm S, Podgornik MN, Coburn SP, et al. Marrow cell transplantation for infantile hypophosphatasia. J Bone Miner Res (2003) 18:624-36. doi:10.1359/jbmr.2003.18.4.624
179. Eggenhofer E, Benseler V, Kroemer A, Popp FC, Geissler EK, Schlitt HJ, et al. Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion. Front Immunol (2012) 3:297. doi:10.3389/fimmu.2012.00297
180. Plock JA, Schnider JT, Schweizer R. Are cultured mesenchymal stromal cells an option for immunomodulation in transplantation? Front Immunol (2013) 4:41. doi:10.3389/fimmu.2013.00041
181. Wagner W, Ho AD, Zenke M. Different facets of aging in human mesenchymal stem cells. Tissue Eng Part B Rev (2010) 16:445-53. doi:10.1089/ten.TEB.2009.0825
182. Vacanti V, Kong E, Suzuki G, Sato K, Canty JM, Lee T. Phenotypic changes of adult porcine mesenchymal stem cells induced by prolonged passaging in culture. J Cell Physiol (2005) 205:194-201. doi:10.1002/jcp.20376
183. Djouad F, Plence P, Bony C, Tropel P, Apparailly F, Sany J, et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood (2003) 102:3837-44. doi:10.1182/blood-2003-04-1193
184. Tolar J, Nauta AJ, Osborn MJ, Panoskaltsis Mortari A, McElmurry RT, Bell S, et al. Sarcoma derived from cultured mesenchymal stem cells. Stem Cells (2007) 25:371-9. doi:10.1634/stemcells.2005-0620
185. Lee RH, Yoon N, Reneau JC, Prockop DJ. Preactivation of human MSCs with TNF-a enhances tumor-suppressive activity. Cell Stem Cell (2012) 11:825-35. doi:10.1016/j.stem.2012.10.001
186. Lazarus HM, Haynesworth SE, Gerson SL, Rosenthal NS, Caplan AI. Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use. Bone Marrow Transplant (1995) 16:557-64.
187. McKernan R, McNeish J, Smith D. Pharma's developing interest in stem cells. Cell Stem Cell (2010) 6:517-20. doi:10.1016/j.stem.2010.05.012
188. Griffin MD, Elliman SJ, Cahill E, English K, Ceredig R, Ritter T. Concise review: adult mesenchymal stromal cell therapy for inflammatory diseases: how well are we joining the dots? Stem Cells (2013) 31:2033-41. doi:10.1002/stem.1452